The Drug-Induced Respiratory Disease Website
Hypersensitivity and infusion reactions. May mimic systemic vasculitis (PMID 30746133). See also under 'Anaphylaxis' (Xf). Hypersensitivity reactions include the rapid development of malaise, cough, dyspnea, wheezing-bronchospasm, cutaneous rash, itching and pruritus. These symptoms may annunciate the onset of anaphylaxis (see Xf) especially if the drug is continued or the patient is inadvertenly rechallenged with the drug. Desensitization can be offered (PMID 26895621), so that patients can receive full treatment courses and need not be switched to an alternative, potentially more toxic or inferior therapy. See PMID 12634903, 12721396, 22149339, 22987983. Skin manifestations at PMID 24820798
Publications
Safety-related regulatory actions for biologicals approved in the United States and the European Union.
JAMA 2008 Oct 22;300;1887-96 — 2008 Oct 22 — 1887-96
Management and preparedness for infusion and hypersensitivity reactions.
The oncologist 2007 May;12;601-9 — 2007 May — 601-9
Tada K, Ito Y, Hatake K, Okudaira T, Watanabe J, Arakawa M, Miyazato M, Irie T, Mizunuma N, Takahashi S, Aiba K, Horikoshi N, Kasumi F
Severe infusion reaction induced by trastuzumab: a case report.
Breast cancer (Tokyo, Japan) 2003;10;167-9 — 2003 — 167-9